Agios Pharm

Price Chart

Risk-Adjusted Performance

Also Listed On

Agios Pharm (AGIO) Price Performance

Agios Pharm (AGIO) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $26.29, down 25.18% from the previous close.

Over the past year, AGIO has traded between a low of $22.34 and a high of $45.49. The stock has lost 7.3% over this period. It is currently 42.2% below its 52-week high.

Agios Pharm has a market capitalization of $1.63B.

About Agios Pharm

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Compare Agios Pharm

Side-by-side comparison against top Healthcare peers.